Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06418412
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-13
Brief Title:
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Sponsor:
National Cancer Centre Singapore
Organization:
National Cancer Centre Singapore
Study Overview
Official Title:
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer NSCLC
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia In addition there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies
This study aims to fill this knowledge gap by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients
This study aims to fill this knowledge gap by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients
Detailed Description:
This study will be a multi-center observational study and will enroll patients with advanced EGFR exon 20 insertion mutated NSCLC
The study will include patients recruited from countries across Asia including sites in but not limited to - Hong Kong Korea Singapore Taiwan and Thailand There will be approximately 20-30 sites recruiting for the study In Singapore sites may include National Cancer Centre Singapore NCCS National University Hospital NUH and Tan Tock Seng Hospital TTSH
Approximately 600 patients will be enrolled retrospectively
The study will include patients recruited from countries across Asia including sites in but not limited to - Hong Kong Korea Singapore Taiwan and Thailand There will be approximately 20-30 sites recruiting for the study In Singapore sites may include National Cancer Centre Singapore NCCS National University Hospital NUH and Tan Tock Seng Hospital TTSH
Approximately 600 patients will be enrolled retrospectively
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None